Skip to main content
. 2018 Mar 27;19:49. doi: 10.1186/s12931-018-0749-4

Table 1.

Baseline characteristics

Characteristic All included patients (N = 79) Morning symptom score < 17.0 (N = 41) Morning symptom score ≥ 17.0 (N = 38) Difference (P-value)
Age in years, mean (SD) 65.6 (8.8) 66.4 (8.2) 64.7 (9.4) 0.38
Male, n (%) 42 (53) 25 (61) 17 (45) 0.15
Ethnicity Caucasian, n (%) 78 (99) 40 (98) 38 (100) 0.33
Current smoking, n (%) 21 (27) 8 (20) 13 (34) 0.14
Pack years, median [IQR] 37 [25–51] 34 [25–42] 41 [26–71] 0.06
In current employment, n (%) 21 (27) 12 (29) 9 (24) 0.58
BMI in kg/m2, mean (SD) 26.4 (5.1) 25.5 (4.8) 27.3 (5.3) 0.13
FEV1/FVC ratio, mean (SD) 45.5 (12.2) 45.6 (13.6) 45.5 (10.6) 0.99
FEV1% predicted, mean (SD) 55.2 (16.9) 57.2 (19.3) 53.0 (14.0) 0.28
Exacerbation in the previous year, n (%) 41 (52) 16 (39) 25 (66) 0.017
GOLD stage
 A, n (%) 19 (24.1) 17 (41.5) 2 (5.3) < 0.001
 B, n (%) 22 (27.8) 9 (22.0) 13 (34.2) 0.23
 C, n (%) 6 (7.6) 6 (14.6) 0 (0.0) 0.014
 D, n (%) 32 (40.5) 9 (22.0) 23 (60.5) < 0.001
CCQ total score, mean (SD) 2.1 (1.1) 1.4 (0.86) 2.8 (0.9) < 0.001
SGRQ total score, mean (SD) 43.0 (18.6) 32.1 (16.6) 54.8 (12.4) < 0.001
Long-acting bronchodilation
 Use of one long-acting bronchodilator, n (%) 17 (21.5) 10 (24.4) 7 (18.4) 0.52
 Use of two long-acting bronchodilators, n (%)) 58 (74.7) 28 (68.3) 31 (81.6) 0.18
 No long-acting bronchodilator, n (%) 3 (3.8) 3 (7.3) 0 (0.0) 0.09
CCI score, median [IQR] 2 [1–3] 2 [1–3] 2 [1–3] 0.98
 History of solid tumor without metastasis, n (%) 15 (19.0) 9 (22.0) 6 (15.8) 0.49
 Cerebrovascular disease, n (%) 10 (12.7) 6 (14.6) 4 (10.5) 0.58
 Uncomplicated diabetes mellitus, n (%) 9 (11.4) 3 (7.3) 6 (15.8) 0.24

BMI body mass index, CCI Charlson comorbidity index, CCQ clinical COPD questionnaire, FEV1 Forced expiratory volume in 1 s, FVC forced vital capacity, GOLD global initiative for chronic obstructive lung disease, IQR interquartile range, SD standard deviation, SGRQ St George Respiratory Questionnaire